Prospective analysis of association between statins and pancreatic cancer risk in the Women’s Health Initiative

Michael S. Simon, Pinkal Desai, Robert Wallace, Chunyuan Wu, Barbara V. Howard, Lisa W. Martin, Nicolas Schlecht, Simin Liu, Allison Jay, Erin S. LeBlanc, Thomas E. Rohan, JoAnn A. Manson

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose: To determine whether HMG-CoA reductase inhibitors (statins) are associated with a lower risk of pancreatic cancer. Methods: The population included 160,578 postmenopausal women enrolled in the Women’s Health Initiative (WHI) in which 385 incident cases of pancreatic cancer were identified over an average of 8.69 (SD ±4.59) years. All diagnoses were confirmed by medical record and pathology review. Information on statin use and other risk factors was collected at baseline and during follow-up. Multivariable-adjusted hazards ratios (HRs) and 95 % confidence intervals (CIs) evaluating the relationship between prior statin use (at baseline only as well as in a time-dependent manner) and risk of pancreatic cancer were computed from Cox proportional hazards regression analyses after adjusting for appropriate confounders. We also evaluated the effect of statin type, potency, lipophilic status, and duration of use. All statistical tests were two-sided. Results: Statins were used at baseline by 12,243 (7.5 %) women. The annualized rate of pancreatic cancer in statin users and nonusers, respectively, was 0.0298 versus 0.0271 %. The multivariable-adjusted HR for statin users versus nonusers at baseline was 0.92 and 95 % CI 0.57–1.48. In a time-dependent model, the HR for low-potency statins was 0.46, 95 % CI 0.20–1.04. There was no significant effect seen by statin lipophilicity or duration of use. Conclusions: There was no significant relationship between statins and pancreatic cancer risk in the WHI; however, there was a marginal inverse association noted for low-potency statins. Analyses of larger numbers of cases are needed to further explore this relationship.

Original languageEnglish (US)
Pages (from-to)415-423
Number of pages9
JournalCancer Causes and Control
Volume27
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Women's Health
Pancreatic Neoplasms
Confidence Intervals
Medical Records

Keywords

  • Cancer risk
  • Pancreatic cancer
  • Statins

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Simon, M. S., Desai, P., Wallace, R., Wu, C., Howard, B. V., Martin, L. W., ... Manson, J. A. (2016). Prospective analysis of association between statins and pancreatic cancer risk in the Women’s Health Initiative. Cancer Causes and Control, 27(3), 415-423. https://doi.org/10.1007/s10552-016-0717-6

Prospective analysis of association between statins and pancreatic cancer risk in the Women’s Health Initiative. / Simon, Michael S.; Desai, Pinkal; Wallace, Robert; Wu, Chunyuan; Howard, Barbara V.; Martin, Lisa W.; Schlecht, Nicolas; Liu, Simin; Jay, Allison; LeBlanc, Erin S.; Rohan, Thomas E.; Manson, JoAnn A.

In: Cancer Causes and Control, Vol. 27, No. 3, 01.03.2016, p. 415-423.

Research output: Contribution to journalArticle

Simon, MS, Desai, P, Wallace, R, Wu, C, Howard, BV, Martin, LW, Schlecht, N, Liu, S, Jay, A, LeBlanc, ES, Rohan, TE & Manson, JA 2016, 'Prospective analysis of association between statins and pancreatic cancer risk in the Women’s Health Initiative', Cancer Causes and Control, vol. 27, no. 3, pp. 415-423. https://doi.org/10.1007/s10552-016-0717-6
Simon, Michael S. ; Desai, Pinkal ; Wallace, Robert ; Wu, Chunyuan ; Howard, Barbara V. ; Martin, Lisa W. ; Schlecht, Nicolas ; Liu, Simin ; Jay, Allison ; LeBlanc, Erin S. ; Rohan, Thomas E. ; Manson, JoAnn A. / Prospective analysis of association between statins and pancreatic cancer risk in the Women’s Health Initiative. In: Cancer Causes and Control. 2016 ; Vol. 27, No. 3. pp. 415-423.
@article{16f5e53ae4714666b923912a44ba8bf4,
title = "Prospective analysis of association between statins and pancreatic cancer risk in the Women’s Health Initiative",
abstract = "Purpose: To determine whether HMG-CoA reductase inhibitors (statins) are associated with a lower risk of pancreatic cancer. Methods: The population included 160,578 postmenopausal women enrolled in the Women’s Health Initiative (WHI) in which 385 incident cases of pancreatic cancer were identified over an average of 8.69 (SD ±4.59) years. All diagnoses were confirmed by medical record and pathology review. Information on statin use and other risk factors was collected at baseline and during follow-up. Multivariable-adjusted hazards ratios (HRs) and 95 {\%} confidence intervals (CIs) evaluating the relationship between prior statin use (at baseline only as well as in a time-dependent manner) and risk of pancreatic cancer were computed from Cox proportional hazards regression analyses after adjusting for appropriate confounders. We also evaluated the effect of statin type, potency, lipophilic status, and duration of use. All statistical tests were two-sided. Results: Statins were used at baseline by 12,243 (7.5 {\%}) women. The annualized rate of pancreatic cancer in statin users and nonusers, respectively, was 0.0298 versus 0.0271 {\%}. The multivariable-adjusted HR for statin users versus nonusers at baseline was 0.92 and 95 {\%} CI 0.57–1.48. In a time-dependent model, the HR for low-potency statins was 0.46, 95 {\%} CI 0.20–1.04. There was no significant effect seen by statin lipophilicity or duration of use. Conclusions: There was no significant relationship between statins and pancreatic cancer risk in the WHI; however, there was a marginal inverse association noted for low-potency statins. Analyses of larger numbers of cases are needed to further explore this relationship.",
keywords = "Cancer risk, Pancreatic cancer, Statins",
author = "Simon, {Michael S.} and Pinkal Desai and Robert Wallace and Chunyuan Wu and Howard, {Barbara V.} and Martin, {Lisa W.} and Nicolas Schlecht and Simin Liu and Allison Jay and LeBlanc, {Erin S.} and Rohan, {Thomas E.} and Manson, {JoAnn A.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1007/s10552-016-0717-6",
language = "English (US)",
volume = "27",
pages = "415--423",
journal = "Cancer Causes and Control",
issn = "0957-5243",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Prospective analysis of association between statins and pancreatic cancer risk in the Women’s Health Initiative

AU - Simon, Michael S.

AU - Desai, Pinkal

AU - Wallace, Robert

AU - Wu, Chunyuan

AU - Howard, Barbara V.

AU - Martin, Lisa W.

AU - Schlecht, Nicolas

AU - Liu, Simin

AU - Jay, Allison

AU - LeBlanc, Erin S.

AU - Rohan, Thomas E.

AU - Manson, JoAnn A.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Purpose: To determine whether HMG-CoA reductase inhibitors (statins) are associated with a lower risk of pancreatic cancer. Methods: The population included 160,578 postmenopausal women enrolled in the Women’s Health Initiative (WHI) in which 385 incident cases of pancreatic cancer were identified over an average of 8.69 (SD ±4.59) years. All diagnoses were confirmed by medical record and pathology review. Information on statin use and other risk factors was collected at baseline and during follow-up. Multivariable-adjusted hazards ratios (HRs) and 95 % confidence intervals (CIs) evaluating the relationship between prior statin use (at baseline only as well as in a time-dependent manner) and risk of pancreatic cancer were computed from Cox proportional hazards regression analyses after adjusting for appropriate confounders. We also evaluated the effect of statin type, potency, lipophilic status, and duration of use. All statistical tests were two-sided. Results: Statins were used at baseline by 12,243 (7.5 %) women. The annualized rate of pancreatic cancer in statin users and nonusers, respectively, was 0.0298 versus 0.0271 %. The multivariable-adjusted HR for statin users versus nonusers at baseline was 0.92 and 95 % CI 0.57–1.48. In a time-dependent model, the HR for low-potency statins was 0.46, 95 % CI 0.20–1.04. There was no significant effect seen by statin lipophilicity or duration of use. Conclusions: There was no significant relationship between statins and pancreatic cancer risk in the WHI; however, there was a marginal inverse association noted for low-potency statins. Analyses of larger numbers of cases are needed to further explore this relationship.

AB - Purpose: To determine whether HMG-CoA reductase inhibitors (statins) are associated with a lower risk of pancreatic cancer. Methods: The population included 160,578 postmenopausal women enrolled in the Women’s Health Initiative (WHI) in which 385 incident cases of pancreatic cancer were identified over an average of 8.69 (SD ±4.59) years. All diagnoses were confirmed by medical record and pathology review. Information on statin use and other risk factors was collected at baseline and during follow-up. Multivariable-adjusted hazards ratios (HRs) and 95 % confidence intervals (CIs) evaluating the relationship between prior statin use (at baseline only as well as in a time-dependent manner) and risk of pancreatic cancer were computed from Cox proportional hazards regression analyses after adjusting for appropriate confounders. We also evaluated the effect of statin type, potency, lipophilic status, and duration of use. All statistical tests were two-sided. Results: Statins were used at baseline by 12,243 (7.5 %) women. The annualized rate of pancreatic cancer in statin users and nonusers, respectively, was 0.0298 versus 0.0271 %. The multivariable-adjusted HR for statin users versus nonusers at baseline was 0.92 and 95 % CI 0.57–1.48. In a time-dependent model, the HR for low-potency statins was 0.46, 95 % CI 0.20–1.04. There was no significant effect seen by statin lipophilicity or duration of use. Conclusions: There was no significant relationship between statins and pancreatic cancer risk in the WHI; however, there was a marginal inverse association noted for low-potency statins. Analyses of larger numbers of cases are needed to further explore this relationship.

KW - Cancer risk

KW - Pancreatic cancer

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=84958770085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958770085&partnerID=8YFLogxK

U2 - 10.1007/s10552-016-0717-6

DO - 10.1007/s10552-016-0717-6

M3 - Article

VL - 27

SP - 415

EP - 423

JO - Cancer Causes and Control

JF - Cancer Causes and Control

SN - 0957-5243

IS - 3

ER -